3/5
08:42 am
regn
2 Biotech Giants to Buy in 2026 [Yahoo! Finance]
Low
Report
2 Biotech Giants to Buy in 2026 [Yahoo! Finance]
3/4
10:22 am
regn
Jim Cramer Says “I Should Have Pulled the Trigger on Regeneron” [Yahoo! Finance]
Low
Report
Jim Cramer Says “I Should Have Pulled the Trigger on Regeneron” [Yahoo! Finance]
3/3
02:32 pm
regn
These 5 New York companies are among America's best employers [USA TODAY]
Low
Report
These 5 New York companies are among America's best employers [USA TODAY]
3/2
11:54 am
regn
Regeneron Pharmaceuticals (REGN) had its price target raised by Royal Bank Of Canada from $745.00 to $765.00. They now have a "sector perform" rating on the stock.
Low
Report
Regeneron Pharmaceuticals (REGN) had its price target raised by Royal Bank Of Canada from $745.00 to $765.00. They now have a "sector perform" rating on the stock.
3/1
05:38 pm
regn
Regeneron's Dupixent Win And Rare Disease Push Reshape Risk Reward Profile [Yahoo! Finance]
Low
Report
Regeneron's Dupixent Win And Rare Disease Push Reshape Risk Reward Profile [Yahoo! Finance]
2/28
03:23 am
regn
Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq? [Yahoo! Finance]
Low
Report
Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq? [Yahoo! Finance]
2/28
02:32 am
regn
Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds [Yahoo! Finance]
Low
Report
Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds [Yahoo! Finance]
2/27
10:58 am
regn
EMA panel recommends Dupixent indication for urticaria in children [Seeking Alpha]
Low
Report
EMA panel recommends Dupixent indication for urticaria in children [Seeking Alpha]
2/27
08:01 am
regn
Why Dupixent Keeps Regeneron A Top Big Pharma Pick [Seeking Alpha]
Low
Report
Why Dupixent Keeps Regeneron A Top Big Pharma Pick [Seeking Alpha]
2/27
07:22 am
regn
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment [Yahoo! Finance]
Low
Report
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment [Yahoo! Finance]
2/27
07:00 am
regn
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
Low
Report
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
2/26
12:24 pm
regn
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders [Yahoo! Finance]
Low
Report
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders [Yahoo! Finance]
2/26
12:03 pm
regn
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
Low
Report
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
2/26
12:00 pm
regn
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
Low
Report
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders
2/24
09:30 am
regn
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
Low
Report
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
2/24
02:29 am
regn
FDA Accepts Regeneron (REGN) BLA for Garetosmab Under Priority Review [Yahoo! Finance]
Low
Report
FDA Accepts Regeneron (REGN) BLA for Garetosmab Under Priority Review [Yahoo! Finance]
2/20
11:36 am
regn
Is Wall Street Bullish or Bearish on Regeneron Pharmaceuticals Stock? [Yahoo! Finance]
Low
Report
Is Wall Street Bullish or Bearish on Regeneron Pharmaceuticals Stock? [Yahoo! Finance]
2/19
07:00 am
regn
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
Low
Report
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
2/16
01:08 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at
Wa
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at
Wa
2/13
07:02 pm
regn
Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts? [Yahoo! Finance]
Low
Report
Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts? [Yahoo! Finance]
2/11
04:05 pm
regn
Regeneron Announces Investor Conference Presentations
Low
Report
Regeneron Announces Investor Conference Presentations
2/10
07:02 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
2/10
07:00 am
regn
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
Low
Report
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
2/9
10:05 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Guggenheim from $865.00 to $975.00. They now have a "buy" rating on the stock.
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Guggenheim from $865.00 to $975.00. They now have a "buy" rating on the stock.
2/8
02:04 am
regn
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at
Wall
Low
Report
Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by analysts at
Wall